Oramed Pharmaceuticals
ORMP
21 hedge funds and large institutions have $1.32M invested in Oramed Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 4 closing their positions.
2,024% more call options, than puts
Call options by funds: $1.08M | Put options by funds: $51K
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
16% less funds holding
Funds holding: 25 → 21 (-4)
28% less capital invested
Capital invested by funds: $1.84M → $1.32M (-$523K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$57.5K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$30.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$10K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.87K |
| 5 |
PCM
Penserra Capital Management
Orinda,
California
|
+$4.93K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$175K |
| 2 |
Millennium Management
New York
|
-$140K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
-$66.1K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$13K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$11.7K |
ORMP Hedge Fund Activity: Q3 2016 in Review
21 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2016, worth a combined $1.32M — down 28% from $1.84M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ORMP and 0 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was PNC Financial Services Group, adding an estimated $57.5K. The largest seller was Morgan Stanley, cutting an estimated $175K.
- 21 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2016, down from 25 in Q2 2016.
- Funds reported $1.32M of Oramed Pharmaceuticals stock for Q3 2016, down 28% quarter-over-quarter.
- 0 funds opened new Oramed Pharmaceuticals positions in Q3 2016 and 4 closed out, a net change of -4 holders.
- The largest Oramed Pharmaceuticals buyer in Q3 2016 was PNC Financial Services Group, an estimated $57.5K added.
- The largest Oramed Pharmaceuticals seller in Q3 2016 was Morgan Stanley, an estimated $175K sold.
Based on aggregated 13F filings for Q3 2016.